United Therapeutics Is Maintained at Outperform by Oppenheimer
United Therapeutics Analyst Ratings
Oppenheimer Maintains United Therapeutics(UTHR.US) With Buy Rating, Raises Target Price to $575
Leerink Partners Maintains United Therapeutics(UTHR.US) With Buy Rating, Raises Target Price to $375
Morgan Stanley Maintains United Therapeutics(UTHR.US) With Hold Rating, Maintains Target Price $337
United Therapeutics Analyst Ratings
A Quick Look at Today's Ratings for United Therapeutics(UTHR.US), With a Forecast Between $337 to $380
TD Cowen Maintains United Therapeutics(UTHR.US) With Buy Rating, Maintains Target Price $350
H.C. Wainwright Maintains United Therapeutics(UTHR.US) With Buy Rating, Maintains Target Price $400
Morgan Stanley Downgrades United Therapeutics(UTHR.US) to Hold Rating, Raises Target Price to $337
Oppenheimer Maintains United Therapeutics(UTHR.US) With Buy Rating, Maintains Target Price $400
A Quick Look at Today's Ratings for United Therapeutics(UTHR.US), With a Forecast Between $280 to $400
United Therapeutics (UTHR) Gets a Buy From Oppenheimer
United Therapeutics Analyst Ratings
Ladenburg Thalmann Downgrades United Therapeutics to Neutral From Buy, $319 Price Target
HC Wainwright Adjusts Price Target on United Therapeutics to $400 From $300, Maintains Buy Rating
H.C. Wainwright Maintains United Therapeutics(UTHR.US) With Buy Rating, Raises Target Price to $400
United Therapeutics Analyst Ratings
Wells Fargo Sticks to Its Buy Rating for United Therapeutics (UTHR)
TD Cowen Adjusts Price Target on United Therapeutics to $350 From $270, Maintains Buy Rating